VKTX vs DBVT vs NVO vs IQV vs MRK

For growth investors, Novo Nordisk A/S (NVO) is the stronger pick with 6.

4% revenue growth year-over-year, versus 1. 2% for Merck & Co. , Inc. (MRK). Novo Nordisk A/S (NVO) offers the better valuation at 12. 6x trailing P/E (2. 1x forward), making it the more compelling value choice. Analysts rate Viking Therapeutics, Inc. (VKTX) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Novo Nordisk A/S (NVO) is the cheapest at 12.

6x versus IQVIA Holdings Inc. at 22. 8x. On forward P/E, Novo Nordisk A/S is actually cheaper at 2. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Novo Nordisk A/S wins at 0. 10x versus Merck & Co. , Inc. 's 1. 03x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Viking Therapeutics, Inc.

(VKTX) delivered a total return of +435. 3%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: VKTX returned +25. 8% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Merck & Co.

, Inc. (MRK) is the lower-risk stock at 0. 48β versus Viking Therapeutics, Inc. 's 1. 61β — meaning VKTX is approximately 238% more volatile than MRK relative to the S&P 500. On balance sheet safety, Viking Therapeutics, Inc. (VKTX) carries a lower debt/equity ratio of 0% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Novo Nordisk A/S (NVO) is pulling ahead at 6.

4% versus 1. 2% for Merck & Co. , Inc. (MRK). On earnings-per-share growth, the picture is similar: Merck & Co. , Inc. grew EPS 8. 0% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, NVO leads at 20. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novo Nordisk A/S (NVO) is the more profitable company, earning 33.

1% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 33. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVO leads at 41. 3% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — NVO leads at 81. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Novo Nordisk A/S (NVO) is the more undervalued stock at a PEG of 0. 10x versus Merck & Co. , Inc. 's 1. 03x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Novo Nordisk A/S (NVO) trades at 2. 1x forward P/E versus 21. 9x for Merck & Co. , Inc. — 19. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VKTX: 219. 0% to $100. 75.

In this comparison, NVO (4.

0% yield), MRK (2. 9% yield) pay a dividend. VKTX, DBVT, IQV do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Merck & Co.

, Inc. (MRK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 48), 2. 9% yield, +166. 5% 10Y return). Viking Therapeutics, Inc. (VKTX) carries a higher beta of 1. 61 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MRK: +166. 5%, VKTX: +25. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VKTX is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; NVO is a large-cap deep-value stock; IQV is a mid-cap quality compounder stock; MRK is a large-cap deep-value stock. NVO, MRK pay a dividend while VKTX, DBVT, IQV do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.